SEARCH RESULTS FOR:

Nick Grasman

LEAD MARKET MANAGER, DOW PHARMA SOLUTIONS, THE DOW CHEMICAL COMPANY
United States Biopharmaceuticals 2018
Dow Pharma Solutions develops functional excipients and APIs that enable improved pharmaceutical delivery and enhanced solubility.

Steve Dixon

CEO, STRACON
Peru Mining 2018 Pre-Release
STRACON’s CEO, Steve Dixon, provides its vision and strategy as it enters a new phase under new owners.

Infectious Diseases: Addressing Growing Resistance

United States Biopharmaceuticals 2018
The infectious disease space is one of high unmet need. However, this particular market segment carries an additional challenge: drug resistance.

Singapore’s Chemicals Sector is Undergoing a Transformation

Singapore Chemicals 2018
Only in Singapore do government interventions and free markets enjoy such harmonious symbiosis.

Jay Dong

GENERAL MANAGER and GLOBAL VP, CST CHINA
CST is expanding its footprint across China where R&D and innovation spending is on the rise.

Paul Fong

SINGAPORE AND MALAYSIA COUNTRY MANAGER, DOW CHEMICAL
Singapore Chemicals 2018
“Rather than seeing the market adoption of sustainable products as a challenge, I view it as a process of educating the entire value chain; a matter of technological proliferation […]”

Mickey Kertesz

FOUNDER & CEO, KARIUS
United States Biopharmaceuticals 2018
The Karius test harnesses next-generation sequencing to detect fragments of cell-free DNA from bacteria, viruses, fungi and protozoa that may be circulating in a patient’s bloodstream.

Gilles Duqueine & Stéphanie Burgun

PRESIDENT AND CEO & DIRECTOR GENERAL, DUQUEINE RHÔNE-ALPES
The Duqueine Group specializes in the development and production of composite parts for the aerospace industry.

Matthias Vorbeck

GENERAL MANAGER, ANASTACIO OVERSEAS
Mexico Petrochemicals and Chemicals 2018 APLA Pre-Release
Anastacio Overseas trades in chemicals sourcing from around the world to supply the Latin American market.

William Hait

GLOBAL HEAD, JOHNSON & JOHNSON GLOBAL EXTERNAL INNOVATION
United States Biopharmaceuticals 2018
Johnson & Johnson invested US$10 billion in research and development in 2017 both internally and externally.

MACIG

SPANISH

SUBSCRIBE TO OUR NEWSLETTER

RECENT PUBLICATIONS

United States Life Sciences 2025 - Digital Interactive

Resilience amid uncertainty. These words encapsulate the US life sciences sector as it navigates 2025. While the industry has largely rebounded from the recent biotech bear market, with clinical trial starts and funding showing signs of rebound, headwinds remain.

PARTNER EVENTS